Viewing Study NCT05228951


Ignite Creation Date: 2025-12-24 @ 11:52 PM
Ignite Modification Date: 2025-12-25 @ 9:47 PM
Study NCT ID: NCT05228951
Status: RECRUITING
Last Update Posted: 2022-09-13
First Post: 2022-01-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
Sponsor: Shengjing Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module